Alliancebernstein L.P. maintained its stake in Imperva Inc (NYSE:IMPV) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 47,850 shares of the software maker’s stock at the end of the first quarter. Alliancebernstein L.P.’s holdings in Imperva were worth $1,964,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Kalmar Investments Inc. DE raised its stake in Imperva by 0.4% in the first quarter. Kalmar Investments Inc. DE now owns 39,808 shares of the software maker’s stock valued at $1,634,000 after buying an additional 140 shares during the period. American International Group Inc. raised its stake in Imperva by 7.1% in the first quarter. American International Group Inc. now owns 17,657 shares of the software maker’s stock valued at $725,000 after buying an additional 1,167 shares during the period. Teachers Advisors LLC raised its stake in Imperva by 4.4% in the fourth quarter. Teachers Advisors LLC now owns 47,262 shares of the software maker’s stock valued at $1,815,000 after buying an additional 1,972 shares during the period. Bank of New York Mellon Corp raised its stake in Imperva by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 125,398 shares of the software maker’s stock valued at $5,148,000 after buying an additional 2,295 shares during the period. Finally, Ameritas Investment Partners Inc. bought a new stake in Imperva during the first quarter valued at approximately $102,000. Hedge funds and other institutional investors own 92.72% of the company’s stock.

Shares of Imperva Inc (NYSE:IMPV) opened at 51.60 on Thursday. Imperva Inc has a 12 month low of $34.40 and a 12 month high of $57.24. The stock’s 50 day moving average is $49.29 and its 200 day moving average is $44.65. The stock’s market capitalization is $1.73 billion.

Imperva (NYSE:IMPV) last posted its earnings results on Thursday, May 4th. The software maker reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.33. The company had revenue of $72.31 million for the quarter, compared to analyst estimates of $68.16 million. Imperva had a net margin of 31.92% and a return on equity of 36.67%. Imperva’s revenue was up 21.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.25) EPS. Analysts anticipate that Imperva Inc will post $0.45 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/07/20/alliancebernstein-l-p-has-1964000-position-in-imperva-inc-impv.html.

Several research firms have recently commented on IMPV. ValuEngine lowered Imperva from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. UBS AG started coverage on shares of Imperva in a report on Tuesday, June 6th. They issued a “positive” rating and a $60.00 target price for the company. Stifel Nicolaus reaffirmed a “hold” rating and issued a $47.00 target price on shares of Imperva in a report on Friday, July 14th. Imperial Capital reaffirmed an “outperform” rating and issued a $57.00 target price (up previously from $55.00) on shares of Imperva in a report on Tuesday, May 9th. Finally, Stephens reaffirmed an “overweight” rating and issued a $61.00 target price (up previously from $53.00) on shares of Imperva in a report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $50.29.

In other Imperva news, CRO Michael D. Mooney sold 52,356 shares of the business’s stock in a transaction dated Wednesday, May 10th. The shares were sold at an average price of $47.51, for a total value of $2,487,433.56. Following the transaction, the executive now directly owns 52,356 shares in the company, valued at approximately $2,487,433.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Sunil D. Nagdev sold 4,857 shares of the business’s stock in a transaction dated Tuesday, May 16th. The shares were sold at an average price of $49.00, for a total transaction of $237,993.00. Following the completion of the transaction, the senior vice president now owns 16,290 shares in the company, valued at $798,210. The disclosure for this sale can be found here. Insiders sold a total of 60,302 shares of company stock worth $2,875,861 over the last quarter. 2.20% of the stock is currently owned by company insiders.

Imperva Company Profile

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Want to see what other hedge funds are holding IMPV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Imperva Inc (NYSE:IMPV).

Institutional Ownership by Quarter for Imperva (NYSE:IMPV)

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.